0001209191-21-045948.txt : 20210707 0001209191-21-045948.hdr.sgml : 20210707 20210707203859 ACCESSION NUMBER: 0001209191-21-045948 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210706 FILED AS OF DATE: 20210707 DATE AS OF CHANGE: 20210707 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Detke Michael J. CENTRAL INDEX KEY: 0001770786 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38890 FILM NUMBER: 211078710 MAIL ADDRESS: STREET 1: C/O CORTEXYME, INC. STREET 2: 269 EAST GRAND AVE. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cortexyme, Inc. CENTRAL INDEX KEY: 0001662774 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 269 EAST GRAND AVE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 415-910-5717 MAIL ADDRESS: STREET 1: 269 EAST GRAND AVE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-07-06 0 0001662774 Cortexyme, Inc. CRTX 0001770786 Detke Michael J. C/O CORTEXYME, INC. 269 EAST GRAND AVE. SOUTH SAN FRANCISCO CA 94080 0 1 0 0 Chief Medical Officer Common Stock 2021-07-06 4 M 0 12600 2.23 A 40861 D Common Stock 2021-07-06 4 S 0 32313 53.43 D 8548 D Common Stock 2021-07-06 4 S 0 8260 53.91 D 288 D Common Stock 2021-07-06 4 S 0 288 55.01 D 0 D Common Stock 2021-07-07 4 M 0 17400 2.23 A 17400 D Common Stock 2021-07-07 4 S 0 3934 53.24 D 13466 D Common Stock 2021-07-07 4 S 0 1648 54.37 D 11818 D Common Stock 2021-07-07 4 S 0 4353 55.38 D 7465 D Common Stock 2021-07-07 4 S 0 6942 56.27 D 523 D Common Stock 2021-07-07 4 S 0 523 56.99 D 0 D Stock Option (right to buy) 2.23 2021-07-06 4 M 0 12600 0.00 D 2028-11-27 Common Stock 12600 119752 D Stock Option (right to buy) 2.23 2021-07-07 4 M 0 17400 0.00 D 2028-11-27 Common Stock 17400 102352 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 19, 2021. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.69 to $53.68, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.71 to $54.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.745 to $53.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.75 to $54.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.79 to $55.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.80 to $56.77, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.81 to $57.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The option will vest as to 25% of the shares on November 15, 2019, with the remaining 75% of shares vesting in equal monthly installments beginning on December 15, 2019 and ending on November 15, 2022. /s/ Caryn Gordon McDowell, Attorney-in-Fact for Michael J. Detke, M.D. 2021-07-07